CoChat

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Open access

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated whether empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) improve inflammatory responses in macrophages, identified signalling pathways responsible for these effects, and studied whether the effects can be augmented with dual empagliflozin and gemigliptin therapy. Methods. RAW 264.7 macrophages were first stimulated with lipopolysaccharide (LPS), then cotreated with empagliflozin, gemigliptin, or empagliflozin plus gemigliptin. We conducted quantitative RT-PCR (qRT-PCR) to determine the most effective anti-inflammatory doses without cytotoxicity. We performed ELISA and qRT-PCR for inflammatory cytokines and chemokines and flow cytometry for CD80, the M1 macrophage surface marker, to evaluate the anti-inflammatory effects of empagliflozin and gemigliptin. NF-κB, MAPK, and JAK2/STAT signalling pathways were examined via Western blotting to elucidate the molecular mechanisms of anti-inflammation. Results. LPS-stimulated CD80+ M1 macrophages were suppressed by coincubation with empagliflozin, gemigliptin, and empagliflozin plus gemigliptin, respectively. Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages. These three treatments also attenuated the secretion and mRNA expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10. All of them blocked NF-κB, JNK, and STAT1/3 phosphorylation through IKKα/β, MKK4/7, and JAK2 signalling. Conclusions. Our study demonstrated the anti-inflammatory effects of empagliflozin and gemigliptin via IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 pathway downregulation in macrophages. In all cases, combined empagliflozin and gemigliptin treatment showed greater anti-inflammatory properties.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2021/9944880

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Empagliflozin and gemigliptin diminished LPS-induced proinflammatory response in RAW 264.7 macrophages. Cells were treated with LPS (200 ng/mL) alone, plus the indicated concentrations of (a) empagliflozin (Empa) or (b) gemigliptin (Gemi) for 4 h and proinflammatory cytokines, TNF-α, IL-1β, and IL-6; mRNA expression was analyzed using real-time PCR. (c) Macrophages were treated with LPS alone, plus 500 μM Gemi, 80 μM Empa, or both Gemi and Empa (Gemi+Empa) for 48 h. Cell viabilities were determined via CCK-8 assay. (d) M1 macrophage marker, CD80, was assessed via flow cytometry after 48 h treatment. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups.
Figure 1 Empagliflozin and gemigliptin diminished LPS-induced proinflammatory response in RAW 264.7 macrophages. Cells were treated with LPS (200 ng/mL) alone, plus the indicated concentrations of (a) empagliflozin (Empa) or (b) gemigliptin (Gemi) for 4 h and proinflammatory cytokines, TNF-α, IL-1β, and IL-6; mRNA expression was analyzed using real-time PCR. (c) Macrophages were treated with LPS alone, plus 500 μM Gemi, 80 μM Empa, or both Gemi and Empa (Gemi+Empa) for 48 h. Cell viabilities were determined via CCK-8 assay. (d) M1 macrophage marker, CD80, was assessed via flow cytometry after 48 h treatment. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups.CC BY · PubMed Central
Figure 2 Empagliflozin and gemigliptin reduced PGE2 release and suppressed COX-2 and iNOS gene expression in LPS-activated RAW 264.7 macrophages. (a) Culture supernatants were collected after 48 h treatment, and PGE2 concentration was measured using ELISA. (b) COX-2 and (c) iNOS mRNA expression levels were analysed via real-time PCR after 4 h treatment. (d, e) Western blot assays were conducted to evaluate protein band quantity by densitometry. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups.
Figure 2 Empagliflozin and gemigliptin reduced PGE2 release and suppressed COX-2 and iNOS gene expression in LPS-activated RAW 264.7 macrophages. (a) Culture supernatants were collected after 48 h treatment, and PGE2 concentration was measured using ELISA. (b) COX-2 and (c) iNOS mRNA expression levels were analysed via real-time PCR after 4 h treatment. (d, e) Western blot assays were conducted to evaluate protein band quantity by densitometry. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups.CC BY · PubMed Central
Figure 3 Empagliflozin and gemigliptin inhibited LPS-stimulated proinflammatory cytokines production and attenuated cytokines and chemokines mRNA expression in RAW 264.7 macrophages. (a) The amounts of TNF-α, IL-1β, IL-6, and IFN-γ in the conditioned medium were measured using ELISA after 48 h treatment. (b) TNF-α, IL-1β, IL-6, (c) CCL3, CCL4, CCL5, and CXCL10 mRNA expressions were analysed via real-time PCR after 4 h treatment. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups.
Figure 3 Empagliflozin and gemigliptin inhibited LPS-stimulated proinflammatory cytokines production and attenuated cytokines and chemokines mRNA expression in RAW 264.7 macrophages. (a) The amounts of TNF-α, IL-1β, IL-6, and IFN-γ in the conditioned medium were measured using ELISA after 48 h treatment. (b) TNF-α, IL-1β, IL-6, (c) CCL3, CCL4, CCL5, and CXCL10 mRNA expressions were analysed via real-time PCR after 4 h treatment. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups.CC BY · PubMed Central
Figure 4 Empagliflozin and gemigliptin attenuated the NF-κB, JNK, and STAT signalling pathways in RAW 264.7 macrophages. LPS-stimulated RAW 264.7 macrophages were treated with empagliflozin (Empa), gemigliptin (Gemi), empagliflozin plus gemigliptin (Empa+Gemi), or 50 μM dexamethasone (DEXA) for 4 h. Here, DEXA served as the positive control for the anti-inflammatory reagent. (a) IKKα/β, NF-κB, (b) JAK2, STAT1/3, (c) MAPKs, and (d) MKK4/7 signalling pathways in the cell lysates prepared were measured using Western blotting. Relative expression of each protein was compared. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups. §p < 0.05, §§p < 0.01, and §§§p < 0.001 indicate results with statistically significant differences between DEXA- and Gemi+Empa-treated groups.
Figure 4 Empagliflozin and gemigliptin attenuated the NF-κB, JNK, and STAT signalling pathways in RAW 264.7 macrophages. LPS-stimulated RAW 264.7 macrophages were treated with empagliflozin (Empa), gemigliptin (Gemi), empagliflozin plus gemigliptin (Empa+Gemi), or 50 μM dexamethasone (DEXA) for 4 h. Here, DEXA served as the positive control for the anti-inflammatory reagent. (a) IKKα/β, NF-κB, (b) JAK2, STAT1/3, (c) MAPKs, and (d) MKK4/7 signalling pathways in the cell lysates prepared were measured using Western blotting. Relative expression of each protein was compared. Data are presented as the means ± standard errors from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate comparison with the untreated control. #p < 0.05, ##p < 0.01, and ###p < 0.001 indicate results with statistically significant differences between the LPS-stimulated control and Gemi-, Empa-, or Gemi+Empa-treated groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 indicate results with statistically significant differences between Empa- and Gemi+Empa-treated groups. §p < 0.05, §§p < 0.01, and §§§p < 0.001 indicate results with statistically significant differences between DEXA- and Gemi+Empa-treated groups.CC BY · PubMed Central
Figure 5 Proposal of a proinflammatory pathway inhibited by empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) in LPS-activated RAW 264.7 macrophages.
Figure 5 Proposal of a proinflammatory pathway inhibited by empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) in LPS-activated RAW 264.7 macrophages.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 139

Metadata

Authors
Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J.
Affiliations
Ajou University (KR)
Corresponding author
Kim, Hae Jin
Venue
Journal of Immunology Research
Publisher
Wiley
Published
2021-06-02
Volume
2021
Pages
1-11
ISSN
  • 2314-7156 (ISSN-L)
  • 2314-8861
OpenAlex
W3169937201
Cited by
139
References
66
Citations by year
2026: 19 · 2025: 30 · 2024: 29 · 2023: 36 · 2022: 20 · 2021: 5
FWCI
16.99
Type
journal article
Language
en
Open access
Locations
  • Journal of Immunology Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • AJOU Open Repository (Ajou University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (NRF-2020R1F1A1074019)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords
empagliflozin, gemigliptin, SGLT2 inhibitors, DPP-4 inhibitors, anti-inflammatory activity, macrophages, lipopolysaccharide, NF-κB signaling, JNK signaling, JAK2/STAT3, M1 macrophages, inflammatory cytokines, chemokines, prostaglandin E2, cyclooxygenase-2, inducible nitric oxide synthase, dual therapy, diabetes mellitus, obesity
MeSH terms
RAW 264.7 Cells, Sodium-Glucose Transporter 2 Inhibitors, Animals, Anti-Inflammatory Agents, Benzhydryl Compounds, Glucosides, Lipopolysaccharides, Macrophage Activation, Macrophages, Piperidones, Pyrimidines, Signal Transduction, NF-kappa B, MAP Kinase Kinase 4, MAP Kinase Kinase 7, STAT1 Transcription Factor, Mice, I-kappa B Kinase, Janus Kinase 2, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.